INSIGHTS AND PERSPECTIVES

NEW YORK — The "battle of the bulge" can be won by adding sleep and relaxation to diet and exercise, according to a new study.

Published in the International Journal of Obesity, a study conducted by Kaiser Permanente researchers found that among 472 obese participants with body mass indexes of 30 to 50, weight loss significantly correlated with decreased stress levels.

MENLO PARK, Calif. — Raising Medicare’s eligibility age from 65 to 67 years in 2014 would generate an estimated $7.6 billion in net savings to the federal government, but also would result in an estimated net increase of $5.6 billion in out-of-pocket costs for 65- and 66-year-olds, as well as $4.5 billion in employer retiree healthcare costs, according to a new Kaiser Family Foundation projection of the potential change suggested by several deficit-reduction plans.

LONDON — Any manufacturer that has the necessary resources and still is hesitating about whether to tap into biosimilars might want to go ahead and do it, if projections by British market analysis firm Datamonitor come true.

The firm released a report Monday showing that the global biosimilars market, whose value stood at $243 million in 2010, will increase to $3.7 billion by 2015.

NEW YORK — For many patients, the inability to pay for drugs is enough of a problem, but what if the drugs they need aren’t available at all?

According to a new report by the Premier Healthcare Alliance, more than 240 drugs were hard to find or entirely unavailable, while more than 400 generic versions of branded drugs were backordered for more than five days. Premier said shortages had more than tripled since 2005, with the frequency and effects rising to critical levels and affecting all segments of health care.

NEW YORK — A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

WHAT IT MEANS AND WHY IT’S IMPORTANT — Expectations of improved profitability at Dollar General mean the company will keep the pedal to the metal in terms of expansion.

(THE NEWS: Dollar General keeps growing. For the full story, click here)

WHAT IT MEANS AND WHY IT'S IMPORTANT — In the universe of business partnerships, a joint venture between Teva Pharmaceutical Industries and Procter & Gamble is like two galaxies coming together.

(THE NEWS: P&G, Teva enter partnership. For the full story, click here.)

NATIONAL HARBOR, Md. — A pill developed by AstraZeneca and Pozen that combines a nonsteroidal anti-inflammatory drug with a proton-pump inhibitor was well-tolerated in patients with osteoarthritis, according to a new study.

AstraZeneca announced results of PN400-304, a 12-month study of Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets in patients with osteoarthritis who need daily treatment with NSAIDs but are at risk of NSAID-related gastric ulcers. Vimovo is designed to reduce pain while reducing gastric ulcer risk.